ADVERTISEMENT
Tisotumab Vedotin Improved Survival Outcomes Among Patients With Recurrent or Metastatic Cervical Cancer
At the Society of Gynecological Oncology (SGO) 2024 Annual Meeting, Brian M. Slomovitz, MD, Mount Sinai Medical Center, Miami Beach, Florida, discussed results from the innovaTV 301/ENGOT-cx12/GOG-3057 trial.
Results from this trial demonstrated tisotumab vedotin significantly improved overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) when compared to chemotherapy among patients with second-/third-line recurrent or metastatic cervical cancer.
Source:
Slomovitz B, González-Martín A, Fujiwara K, et al. Efficacy and safety of tisotumab vedotin versus investigator's choice of chemotherapy in 2L or 3L recurrent or metastatic cervical cancer (innovaTV 301/ENGOT-cx12/GOG-3057): A global, randomized, open-label, phase III study. Presented at the Society of Gynecologic Oncology Annual Meeting; March 16-18, 2024. San Diego, California.